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Medicine, University of Texas Medical Branch, Galveston, Texas; 6The McDonnell Genome Institute, Washington University in St. Louis, St. Louis,
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Abstract. Stunting, deﬁned as height-for-age Z score equal to or lower than −2, is associated with increased childhood mortality, cognitive impairment, and chronic diseases. The aim of the study was to investigate the relationship
between linear growth, intestinal damage, and systemic inﬂammation in infants at risk of stunting. We followed up 78
infants aged 5–12 months living in rural areas of Peru for 6 months. Blood samples for biomarkers of intestinal damage
(intestinal fatty-acid–binding protein [I-FABP] and zonulin) and systemic inﬂammation (interleukin-1β, interleukin-6, tumor
necrosis factor α [TNF-α], soluble CD14, and lipopolysaccharide-binding protein [LBP]) and fecal samples for microbiome
analysis were collected at baseline and closure of the study. The children’s growth and health status were monitored
through biweekly home visits by trained staff. Twenty-one percent of the children became stunted: compared with nonstunted children, they had worse nutritional parameters and higher levels of serum I-FABP at baseline. The likelihood of
becoming stunted was strongly associated with an increase in sCD14 over time; LBP and TNF-α showed a trend toward
increase in stunted children but not in controls. The fecal microbiota composition of stunted children had an increased
beta diversity compared with that of healthy controls throughout the study. The relative abundance of Ruminococcus 1
and 2, Clostridium sensu stricto, and Collinsella increased in children becoming stunted but not in controls, whereas
Providencia abundance decreased. In conclusion, stunting in our population was preceded by an increase in markers of
enterocyte turnover and differences in the fecal microbiota and was associated with increasing levels of systemic
inﬂammation markers.

INTRODUCTION

Here, we present the results of a study investigating the
relationship between linear growth, markers of intestinal
damage, and systemic inﬂammation among infants in rural
Peru.

Worldwide, 155 million children are stunted, meaning that
their height or length is less than two SDs from the median
value expected for age and gender.1 Childhood stunting is
associated with increased childhood mortality, cognitive impairment, and a higher risk of chronic diseases later in life2 and,
therefore, represents a serious public health concern. The
suboptimal linear growth may be in part explained by a
chronically inadequate diet. In fact, most stunted individuals
come from food-insecure households.3 However, interventions solely focused on improving nutrition fail to restore their
normal trajectory of growth.4 An alternative or additional cause
may be chronic systemic inﬂammation as suggested by multiple studies showing that stunted children have an increased
level of blood inﬂammation markers.5–8 The origin of this inﬂammatory status could be a sustained, aberrant activation of
the mucosal immune system. Indeed, there is an established
association between stunting and the environmental enteric
disorder (EED), a small-intestine enteropathy highly prevalent
in low-resource countries and characterized by mucosal inﬂammation, small intestine villi ﬂattening, and increased intestinal permeability.9–14 The triggers for this disorder are
probably inadequate diet, continuous exposure to environmental contaminants, and/or an alteration of the normal
commensal ﬂora.

METHODS
Study design and description of the setting. The study
was approved by the Institutional Review Boards of the University of Texas (UT) Health Science Center at Houston, UT
Medical Branch in Galveston, Texas, and the Universidad
Peruana Cayetano Heredia in Lima, Peru. The Ministry of
Health Authorities of Moyobamba and Urubamba endorsed
the study.
This was a pilot prospective study. Infants from two communities of rural Peru were enrolled and followed up for
6 months between December 2014 and May 2015, during the
summer/raining season. The research sites were situated in the
Urubamba district of the Cusco region, in the Peruvian Andes
highlands, and in the Moyobamba district of San Martin region,
in the Northeastern part of the Peruvian Amazon. According to
a 2014 survey (Instituto Nacional de Estadistica e Informatica,
2015), the prevalence of stunting among children aged less than
5 years in the two regions was 18% and 16%, respectively.
Subjects. Infants aged 5–12 months were identiﬁed using
local health centers’ databases. Their families were homevisited by the research team, and written consent was
obtained from both parents. Children were eligible if they had
no history of prematurity, severe chronic illness, or previously
diagnosed failure to thrive; they had a length-for-age Z (LAZ)
score greater than −2 at enrollment; and their families agreed
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on close follow-up. Patients could withdraw from the study at
any time.
At the end of the study, we classiﬁed children as “stunted” if
their last LAZ score at the end of the follow-up was equal to or
lower than −2, whereas we deﬁned “controls” as children who
had a last LAZ score above −2.
Household characteristics and nutritional surveys.
Caregivers were interviewed on enrollment using a structured
questionnaire to gather information regarding family composition and household characteristics. Nutritional surveys were
conducted at the beginning and closure of the study and
aimed at collecting information regarding duration and pattern
of breastfeeding and diet characteristics in the ﬁrst 2 years of
life. A diet diversity score (DDS) was calculated for each child
as per international guidelines.15
Growth monitoring. Participants’ weight and length were
measured at enrollment and monthly thereafter by trained staff
using a calibrated hanging scale and a length board. Weightfor-age Z (WAZ), LAZ, and weight-for-height Z scores were
calculated using WHO Anthro software, version 3.2.2 (World
Health Organization, Geneva, Switzerland).
Health status monitoring. Children were home-visited
every 2 weeks by a trained nurse. At each encounter, information regarding intercurrent episodes of acute illness and
use of antibiotics, as recalled by caregivers, was gathered.
Specimen collection. The study design included collection
of blood samples for the measurement of markers of mucosal
damage and systemic inﬂammation and a fecal sample for
microbiota composition at baseline and the end of follow-up.
Blood samples were collected by venipuncture at the research
center, left to coagulate, and centrifuged to remove the serum
within 5 hours of blood collection. Stool samples for microbiome analysis were collected on the same day of blood
samples and conserved on ice for a maximum of 4 hours.
Serum and stool samples were then frozen in dry shippers and
sent to the reference laboratory where they were stored
at −70°C until analysis.
Measurement of serum biomarkers. Serum-soluble CD14
(sCD14) was assessed using the human magnetic Luminex
screening assay and interleukin-1β (IL-1β), IL-6, and tumor necrosis factor alpha (TNF-α) using the human magnetic Luminex
performance assay (both R&D Systems, Minneapolis, MN)
according to the manufacturer’s protocol. Lipopolysaccharidebinding protein (LBP), intestinal fatty-acid–binding protein (IFABP), and zonulin were measured using commercially available
ELISA kits (Abnova, Taipei City, Taiwan; R&D Systems; and IDK®
Zonulin ELISA kit, Bensheim, Germany, respectively) according
to the manufacturer’s protocol.
Microbiome analysis. Microbial DNA extraction, 16S rRNA
gene ampliﬁcation, and deep-sequencing. Bacterial genomic
DNA was extracted from human feces using the MoBio
PowerMag Microbiome DNA/RNA isolation kit (Carlsbad, CA)
following the manufacturer’s instructions, followed by ampliﬁcation of the V4 regions of the 16S rRNA gene using individually barcoded universal primers containing linker
adapters for Illumina sequencing. Sequencing was performed
using a MiSeq system (Illumina Inc., San Diego, CA).
16S data analysis. Sequence processing and analysis were
performed using speciﬁc software for comparison and analysis of microbial communities (QIIME and mothur). Pair-end
reads of length 2 × 250 bp were demultiplexed and qualityﬁltered according to the following parameters: a required

minimum average quality score of 35 over a 50-bp sliding
window, no homopolymer longer than 6 bp, no ambiguous
bases allowed, two primer mismatches allowed, and one
barcode mismatch allowed. Sequences were clustered and
binned into operational taxonomic units (OTUs) (based on
97% identity), and singleton reads were removed from the
dataset. The resulting OTU table was subsampled to the
smallest number of reads associated with any one sample.
Both the DNA extraction and 16S data analysis were carried
out at the Alkek Center for Metagenomics and Microbiome
Research, Baylor College of Medicine, Houston, Texas.
Statistical analysis. Continuous data distribution was
expressed in terms of medians and interquartile range. A Chisquare test was used to compare categorical data. For each
biomarker, samples with levels below the lower limit of detection were given an arbitrary value equal to one-half of the
value of the lowest measurable level. Similarly, samples with
levels above the upper limit of detection were set as twice the
value of the highest measured level. A Mann–Whitney U test
was used to compare the relative distribution of continuous
variables, unless otherwise speciﬁed. Spearman rank correlation coefﬁcient was used to measure the correlation between continuous variables. Cytokine concentration values
were log10-transformed for regression analysis.
The proportional change in serum biomarkers, measured as
the difference between the baseline and end-of-follow-up
concentration divided by the baseline concentration, was
used as a measure of variation of the biomarkers over time.
Multiple logistic regression models were used to measure
the association between stunting and the change of each
biomarker during the follow-up period, after controlling for age
and LAZ score at enrollment.
For the microbiome analysis, we compared children who
became stunted at the end of the study (N = 16) with a restricted
group of children with an LAZ score above −1.5 at both enrollment and end of follow-up (N = 36), as this classiﬁcation allowed
for the best discrimination of groups (Supplemental Figure 2).
Pairwise Bray–Curtis diversity values were calculated between
each sample pair based on their overall microbiome proﬁles, and
groups of samples were compared using an unpaired two-tailed
t-test with unequal variance (data were normally distributed;
Shapiro–Wilk value of 0.96). The linear discriminant analysis effect size (LEfSe) method16 was used for differential taxa abundance testing, using default recommended settings according to
the authors’ instructions, and an adjusted P £ 0.05 and an linear
discriminant analysis (LDA) effect size > 2 for signiﬁcance. The
LEfSe algorithm performs class comparison tests, validates for
biological consistency, and is able to consider all taxonomic
levels for comparison simultaneously. Taxa were classiﬁed
according to the adjusted P-values for signiﬁcance.
STATA version 12 (StataCorp., College Station, TX),
GraphPad Prism version 6 (La Jolla, CA), MS Excel 2016
(Microsoft Corp., Redmond, WA), and a Galaxy server (LEfSe)
were used for the analysis.
RESULTS
Participants. Seventy-eight children were enrolled in the
study. Three children were withdrawn from the study when
the parents moved away. The baseline characteristics of
the children are reported in Table 1. Individuals from the
two sites were similar in terms of age, gender distribution,
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TABLE 1
Characteristics of the children at baseline, by research site
Median age at enrollment (months) (25th, 75th)
Female, n (%)
Birth weight* (g) (25th, 75th)
Length at birth* (cm) (25th, 75th)
Breastfeeding, any duration (months), n (%)
Length of exclusive breastfeeding (months) (25th, 75th)
Age at introduction of solid food (months) (25th, 75th)
Diet diversity score (25th, 75th)
Consumption of animal foods at least 1/day, n (%)
Household characteristics
Maternal age (years) (25th, 75th)
Level of maternal education, n (%)
None
Grammar school
High school
Technical school or university
Median paternal age (years) (25th, 75th)
No. of people living in the house (25th, 75th)
Households with indoor piped water provision, n (%)
Households with a refrigerator, n (%)
Households connected to public sewage, n (%)
Weekly average expense for food provision (nuevo sol) (25th, 75th)

Urubamba (n = 38)

Moyobamba (n = 40)

P-value

9 (8, 10)
15 (47)
3,346 (3160, 3532)
49.5 (48, 51)
38 (100)
6 (3, 6)
6 (6, 6)
4.5 (4, 5)
30 (80)

8.5 (7–12)
17 (53)
3,310 (3,000, 3,770)
49.5 (48–50)
36 (90)
6 (3, 6)
6 (6, 6)
4 (3, 5)
26 (65)

0.9†
0.8‡
0.9†
0.9†
0.04‡
0.9†
0.1†
0.9†
0.2‡

26.5 (20–32)

26.5 (22–34)

0.6†

0 (0)
1 (2.6)
24 (63.1)
13 (34.2)
28.5 (25–38)
4 (3–5)
38 (100)
19 (50)
32 (84. 2)
140 (100, 150)

1 (2.6)
15 (39.5)
17 (44.7)
5 (13.2)
32.5 (30–40)
5 (4–6)
19 (47.5)
26 (65)
17 (42.5)
50 (40, 50)

< 0.001‡
0.07
0.05†
< 0.001‡
0.1‡
0.001‡
< 0.001†

* Information derived from child’s growth cards.
† Mann–Whitney U-test.
‡ Chi-square test.

anthropometric data, and diet habits, although children from
Moyobamba came from lower socioeconomic status.
Health status and growth trajectories. Every child enrolled in the study received a median of two visits per month.
Overall, the prevalence of acute infections during the 6-month
follow-up was low: we observed a median (IQR) of one (0–2)
episode of diarrhea (> 3 loose or watery stools in 24 hours) per
child in Urubamba and 0 (0–1) episode in Moyobamba (P =
0.05) and two1,2 episodes of upper respiratory tract infections
(nasal congestion, sore throat, or cough with or without fever
> 1 day) in Urubamba and 1 (0–2) in Moyobamba (P = 0.03); no
other episodes of acute illness or hospitalizations were reported. No child in either site received more than one course of
antibiotics during the 6 months of follow-up. We did not observe differences in the incidence of acute infections between
children who became stunted and controls.
Sixty-one of 78 children (79%) presented a decline of their
LAZ scores during the study (Figure 1). By the end of the

follow-up, 16/75 (21%) children met the criteria for deﬁnition of
stunting (LAZ < −2). These children were slightly older at enrollment (median age 10.5 months versus 8 months, P = 0.01),
had lower baseline WAZ scores (−0.82 versus 0.1, P = 0.0002),
had lower baseline LAZ scores (−1.54 versus −0.42, P <
0.0001), and showed a larger decrease in LAZ score over time
than controls at the end of the follow-up (−1.11 versus −0.29,
P = 0.01) (Figures 1 and 2). Based on their birth records, the
birth weight and length of children who became stunted were
not signiﬁcantly lower than those of children who did not become stunted (Supplemental Table 1).
No differences were observed between stunted children
and controls in terms of household characteristics or dietary
patterns, including breastfeeding duration, average (DDS15),
daily consumption of animal food, or weekly household expenditure for food supply (Supplemental Table 1). However,
given the small sample size, nonstatistically signiﬁcant differences should be interpreted with caution.

FIGURE 1. Changes in anthropometric measures during follow-up. (A) Median changes in weight-for-age, length-for-age, and weight-for-length Z
scores during follow-up (75 children) and (B) median change in length-for-age Z score: stunted children (16 children) vs. non-stunted (59 children).
**P < 0.001, Mann–Whitney U-test.
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FIGURE 2. Monthly changes in length-for-age Z (LAZ) score, stunted children (N = 16) vs. non-stunted (N = 59) children. The children
who developed stunting at the end of the follow-up had a lower LAZ
score at enrollment and at each time point during the follow-up (each
point indicates the median value per group; error bars indicate 95%
CI). At the end of the follow-up, the median decrease in LAZ score was
−1.1 for children meeting the criteria for stunting vs. −0.29 for nonstunted children (P = 0.01).

Three children were lost to follow-up between the 4th and
5th months of follow-up. Based on their last available measurement, one had become stunted by the time he left the
study and the other two had shown a decrease in their LAZ
score.
Markers of enteropathy. Sixty-six of 78 children enrolled
had blood samples collected at baseline and the end of the
follow-up; the following results refer to this subset of participants. The remaining eight children had only one sample of
blood collected, either because the parents could not come on
the days set for the blood draw or because they refused a
second venipuncture after the ﬁrst attempt failed.
Intestinal fatty-acid–binding protein is a protein found in the
cytosol of intestinal epithelial cells and released into the
bloodstream on cell death.17 The I-FABP concentrations were
112 pg/mL to 14,959 pg/mL, values much higher than those
reported for healthy children in industrialized countries, 20 to
200 pg/mL.18 In our cohort, only 2/142 serum samples had a
concentration below 200 pg/mL.
Intestinal fatty-acid–binding protein baseline levels were
signiﬁcantly higher in the group of children who later became
stunted (2252 pg/mL versus 1,448 pg/mL, P = 0.005), whereas
there was no difference between the stunted and control
subjects at the end of the study, as I-FABP concentration increased in the latter group (Supplemental Table 2). The I-FABP
concentration change over time, however, was not statistically signiﬁcant between stunted and control groups
(Figure 3A, Supplemental Figure 1).
Zonulin is a protein secreted by viable gut epithelial cells and
is an important modulator of tight junctions.19 The concentration of this marker in our cohort and its change over time
were not signiﬁcantly different between stunted and control
children (Figure 3B, Supplemental Table 2).
Proinﬂammatory cytokines, sCD14, and LBP.
Interleukin-6, IL-1β, and TNF-α are mediators of the acute
phase response and have been implicated in growth delay of
children with chronic inﬂammatory diseases.20 Stunted and
control children had comparable values of serum IL-1β and IL6 at both time points (Figure 3C–E, Supplemental Table 2,
Supplemental Figure 1). Serum TNF-α showed a tendency to
increase more over time in children who became stunted

(proportional change 0.05 versus −0.15, P = 0.10), although
the result was statistically signiﬁcant only when we conducted
the analysis using stricter criteria for controls (only children
who had an LAZ score > 1.5 both at enrollment and closure of
the study; Supplemental Figure 1).
Soluble CD14, which is shed by monocytes after stimulation
by bacterial lipopolysaccharide (LPS), augments macrophage
and neutrophil response to endotoxin. The serum concentration of this marker is elevated in patients with enteropathy
and endotoxemia.21–23 Stunted children and controls had
similar levels of sCD14 at baseline, but by the end of the study
stunted children had signiﬁcantly higher concentrations (median 2.01 × 106 pg/mL versus 1.78 × 106 pg/mL, P < 0.01;
Figure 3F, Supplemental Table 2).
Lipopolysaccharide-binding protein is a type-1 acute phase
protein involved in the systemic response to LPS. 24
Lipopolysaccharide-binding protein levels were similar between stunted children and controls at baseline and showed a
tendency to increase among stunted children, although the
change was not statistically signiﬁcant (0.46 versus −0.14, P =
0.07; Figure 3G, Supplemental Table 2, Supplemental
Figure 1). The change in concentrations of sCD14 and LBP
was strongly correlated (r = 0.76, P < 0.0001; Figure 3H).
Associations between linear growth and biomarkers.
Among stunted children, the baseline log-transformed concentration of I-FABP was strongly and inversely correlated
with change in LAZ scores over the following months
(r = −0.78, P < 0.01; Figure 4A). Conversely, among controls,
the baseline log-transformed concentration of I-FABP was
positively correlated with the change in LAZ scores (r = 0.67,
P = 0.04; Figure 4B). Among stunted children, the logtransformed concentration of I-FABP at the end of the
follow-up showed a modest inverse correlation with change in
LAZ scores, but this was only a statistical trend (Figure 4C).
There was no correlation between the log-transformed concentration of I-FABP at the end of the follow-up and change in
LAZ scores in the control children (Figure 4D).
A binary logistic analysis showed that the odd of becoming
stunted was signiﬁcantly associated with older age at enrollment
(OR 1.4, P = 0.03), a lower length-for-age Z score (LZA) at enrollment (OR 0.08, P = 0.002), and an increase in sCD14 concentration over time (OR 9.7, P = 0.01). No other statistically
signiﬁcant associations were noted between stunting at the end
of the follow-up and change in markers, although there was a
trend toward increased odd of becoming stunted with increasing
levels of LBP (OR 5.4, P = 0.08). In a multiple logistic analysis, the
odds of becoming stunted were still signiﬁcantly associated with
the increase in sCD14 level over time even after controlling for
age and HAZ score at enrollment (OR 8.7, P = 0.03).
Fecal microbiome. Seventy-ﬁve children had two sets of
stool samples available for microbiome studies, but, as described in the Methods section, we only compared the fecal
microbiome of the children stunted at the end of the follow-up
(N = 16) with the microbiome of children whose LAZ score was
above −1.5 throughout the study (N = 36). For this analysis, we
compared children who met the criteria for stunting at the end
of the follow-up (LAZ < −2) with children with an LAZ score
greater than −1.5 at both enrollment and end of the follow-up,
as this classiﬁcation allowed for the best discrimination of data
(Supplemental Figure 2).
The alpha diversity (within-sample diversity) of the fecal
microbiota, measured as the Shannon index, increased with

LINEAR GROWTH, INTESTINAL DAMAGE, AND SYSTEMIC INFLAMMATION

1013

FIGURE 3. Proportional changes in blood levels of seven serum biomarkers during the 6-month follow-up, stunted children (N = 16) vs. nonstunted (N = 59) children. Graphs A–F report medians with the 25th–75th percentile (Mann–Whitney U-test). Graph H shows the correlation between
changes in sCD14 and LBP over time (Spearman rank correlation).

age in both cases and control. We did not observe differences
based on gender, site of residence (highlands versus jungle),
or nutritional status (data not shown), but the study was not
powered to show differences between these subgroups.
With regard to beta diversity (between-sample diversity),
Bray–Curtis analysis (Figure 5) showed that 1) the average
beta diversity of intestinal microbiota was signiﬁcantly different between children developing stunting and controls at both
baseline and end of follow-up (P = 0.047 and P = 0.0015,
respectively); 2) control children had a more heterogenous
microbiota composition at enrollment, but heterogeneity decreased over time (P = 0.021); 3) children who developed
stunting had a less heterogenous composition at baseline, but
there was a change toward more diversity (P = 0.0043) at the
end of follow-up (Figure 5).
The relative abundance of bacterial taxa in the gut microbial
communities was assessed using the previously described
LEfSe method. As expected, during the follow-up, we
observed a reduction of taxa belonging to the phylum
Actinobacteria (Biﬁdobacteriaceae) and Proteobacteria

(Enterobacteriaceae) and an increase in taxa belonging to
Firmicutes (members of Lachnospiraceae family, such as
Roseburia, Blautia, and Pseudobutyrivibrio, and Ruminococcaceae family) and Bacteroidetes in both groups. However, when we compared the fecal microbiome of stunted
children versus controls, we observed some differences. The
relative abundance of some speciﬁc genera belonging to the
families of Ruminococcaceae (Ruminococcus 1 and 2) and
Coriobacteriaceae (Collinsella) increased over time in the
children who became stunted but not in children with normal
growth. Conversely, in these children, there was a decrease in
the relative abundance of one genus of Enterobacteriaceae
(Providencia) which was not observed in the microbiome of
controls (Table 2 and Supplemental Figure 3).
DISCUSSION
In this pilot study conducted among Peruvian infants living
in rural regions, we found that 1) during a 6-month observation
period, 79% of the children showed a decrease in their LAZ
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FIGURE 4. Correlation between intestinal fatty-acid–binding protein (I-FABP) levels and change in length-for-age Z scores (LAZ) in stunted
children (16) vs. non-stunted children (59). The concentration of serum I-FABP was inversely correlated with changes in LAZ scores among stunted
children, whereas it seemed to have a weak positive correlation with LAZ score change in children who did not become stunted. r = Spearman
correlation coefﬁcient.

score and 21% developed clinical stunting; 2) almost all participants had higher than expected levels of I-FABP; 3) an
increase in sCD14 was associated with becoming stunted;
and 4) the fecal microbiome of stunting children followed a
different trajectory compared with controls.
This observational study conﬁrms that stunted growth remains a widespread problem, even in countries like Peru
where acute malnutrition is becoming rare. If we consider that
stunting may be the most evident feature of a complex syndrome associated with long-lasting metabolic, immunological, and cognitive changes, the public health relevance of this
phenomenon appears evident.
In our cohort, we did not observe differences in household
wealth, diet, or frequency of acute infections between stunted
and control children, but we did note interesting differences in
the serum concentrations of markers of intestinal cell turnover
and innate immune system activation.
In two repeated occasions, the young infants living in Urubamba and Moyobamba showed levels of serum I-FABP well

FIGURE 5. Bray–Curtis diversity comparisons among fecal microbiome samples collected at baseline and end of follow-up, stunted
children vs. non-stunted children. P-values are calculated using t-test.

above the reference values.22,25,26 Another study conducted
in Zimbabwe on a birth cohort of children living in impoverished conditions reported comparable data.6 Intestinal
fatty-acid–binding protein is almost solely expressed in the
enterocytes of the small intestine and it is more concentrated
in the cells at the top of the villi.17 Studies conducted in patients with celiac disease (a disorder sharing many of the
histological and functional features of EED) showed that this
marker correlates with disease activity and the extent of villi
ﬂattening.18,26 In the few infants included in celiac disease
studies, serum I-FABP levels were extremely high at the time
of diagnosis but rapidly normalized after gluten removal,
probably reﬂecting not only the exquisite vulnerability of a fastgrowing mucosa to external insults but also the potential for
rapid healing.
The relationship between I-FABP levels and linear growth in
cases and controls was contradictory but may be explained by
considering this as a marker of intestinal functional reserve
rather than just enterocyte death.27 Children living in lowresource, unhygienic settings are continuously exposed to a
vast array of intestinal pathogens,28–31 and it is conceivable
that the increased levels of I-FABP represent the accelerated
turnover of a rapidly growing mucosa subjected to ongoing
damage and forced to continuously regenerate itself. In the
presence of a reduced availability of nutrients however, the
rate of mucosal damage may exceed the healing potential of
the host, leading to a vicious cycle of reduction of the enterocyte mass, further compromise of nutrient harvesting,
damage of the intestinal barrier integrity, innate immune activation, and growth delay. It is tempting to hypothesize that
children who developed stunting in our study were already at
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TABLE 2
Gut microbiome analysis: changes in the relative abundance of selected taxa
Not stunted
Phylum

Class

Order

Family

Genus

Taxa with relative abundance increasing over time in stunted children but not in non-stunted
Firmicutes
–
–
–
–
Firmicutes
Clostridia
Clostridiales
Ruminococcaceae
Ruminococcus 1
Firmicutes
Clostridia
Clostridiales
Ruminococcaceae
Ruminococcus 2
Firmicutes
Clostridia
Clostridiales
Ruminococcaceae
Ruminococcaceae UCG 014
Firmicutes
Clostridia
Clostridiales
Lachnospiraceae
–
Firmicutes
Clostridia
Clostridiales
Lachnospiraceae
Uncultured
Firmicutes
Clostridia
Clostridiales
Clostridiaceae 1
Firmicutes
Clostridia
Clostridiales
Clostridiaceae 1
Clostridium sensu stricto 1
Actinobacteria Coriobacteria
Coriobacteriales
Coriobacteriaceae
Collinsella
Taxa with relative abundance increasing over time in both stunted and non-stunted children
Firmicutes
Clostridia
–
–
–
Firmicutes
Clostridia
Clostridiales
–
–
Firmicutes
Clostridia
Clostridiales
Lachnospiraceae
Lachnospiraceae UCG 004
Firmicutes
Clostridia
Clostridiales
Lachnospiraceae
Roseburia
Firmicutes
Clostridia
Clostridiales
Lachnospiraceae
Blautia
Firmicutes
Clostridia
Clostridiales
Lachnospiraceae
Lachnospiraceae NK4A136
group
Firmicutes
Clostridia
Clostridiales
Lachnospiraceae
Fusicatenibacter
Firmicutes
Clostridia
Clostridiales
Lachnospiraceae
Pseudobutyrivibrio
Firmicutes
Clostridia
Clostridiales
Lachnospiraceae
Lachnospiraceae UCG 010
Firmicutes
Clostridia
Clostridiales
Christensenellaceae
–
Firmicutes
Clostridia
Clostridiales
Christensenellaceae
Christensenellaceae R-7
group
Firmicutes
Clostridia
Clostridiales
Family XIII
–
Firmicutes
Clostridia
Clostridiales
Ruminococcaceae
Ruminococcaceae UCG 002
Bacteroidetes
Bacteroidia
Bacteroidales
Porphyromonadaceae Butyricimonas
Taxa with relative abundance decreasing in stunted children but not in non-stunted children
Proteobacteria Gammaproteo- Enterobacteriales Enterobacteriaceae
Providencia
bacteria
Taxa with relative abundance decreasing over time in both stunted and non-stunted children
Actinobacteria
–
–
–
Actinobacteria Actinobacteria
–
–
Actinobacteria Actinobacteria
Biﬁdobacteriales
–
–
Actinobacteria Actinobacteria
Biﬁdobacteriales
Biﬁdobacteriaceae
–
Actinobacteria Actinobacteria
Biﬁdobacteriales
Biﬁdobacteriaceae
Biﬁdobacterium
Proteobacteria Gammaproteo–
–
–
bacteria
Proteobacteria Gammaproteo- Enterobacteriales
–
bacteria
Proteobacteria Gammaproteo- Enterobacteriales Enterobacteriaceae
–
bacteria
Proteobacteria Gammaproteo- Enterobacteriales Enterobacteriaceae
Escherichia–Shigella
bacteria

Stunted

LDA

P-value

LDA

P-value

4.61
2.22
2.59
2.94
4.46
2.12
3.73
3.20
2.39

0.110
0.088
0.615
0.185
0.097
0.068
0.364
0.526
0.693

4.98
2.85
3.05
3.42
4.74
2.64
3.85
3.60
2.59

0.007
0.008
0.025
0.043
0.037
0.012
0.031
0.043
0.035

4.78
4.78
2.14
3.50
3.25
3.44

0.018
0.018
0.008
0.010
0.018
0.004

4.96
4.96
2.78
3.83
3.60
3.91

0.013
0.013
0.002
0.007
0.010
0.017

3.53
4.17
2.55
3.25
3.24

0.013
0.024
0.005
0.001
0.007

3.66
4.04
2.61
2.62
2.61

0.023
0.032
0.048
0.025
0.025

2.01
3.61
2.40

0.031
0.008
0.021

1.99
3.64
2.32

0.028
0.047
0.036

3.07

0.191

2.88

0.036

4.57
4.57
4.56
4.56
4.56
4.70

0.004
0.004
0.005
0.005
0.005
0.013

4.56
4.53
4.53
4.53
4.53
4.71

0.003
0.004
0.004
0.004
0.004
0.048

4.64

0.027

4.79

0.013

4.64

0.027

4.79

0.013

4.59

0.028

4.78

0.014

For the purpose of this analysis, only non-stunted children having an LAZ ³ −1.5 at the end of the follow-up (N = 36) were used as comparison vs. stunted children (deﬁned as children with an LAZ £
−2 at the end of the follow-up) (N = 16) as this classiﬁcation allowed for the best discrimination of data.

the limit of their functional reserve at enrollment and, over the
following, months suffered from a progressive loss of mucosal
surface, which eventually resulted in clinical signs of stunting.
Consistent with other studies,5,6,10 we found stigmata of innate immune activation in children who became clinically
stunted. Both membrane-bound and sCD14 accelerate LPS–
LBP complex recognition by Toll-like receptor-4 on monocytes,
macrophages, and dendritic cells.24 Our sCD14 and LBP
ﬁndings suggest increased microbial translocation across
the intestinal mucosa and increased LPS-induced immune
activation.21,22 Our ﬁndings may indeed signify that the origin of
immune activation in stunted children is a sustained low-grade
microbial translocation through an exhausted intestinal mucosa. They can also partially explain the increased risk of death
due to sepsis, tuberculosis, meningitis, or nonspeciﬁc febrile
episodes in children with severe stunting32 because chronic,
low-grade exposure to bacterial products may induce a status

of tolerance, whereby immune cells become relatively anergic to
endotoxin stimulation,33 or priming, whereby immune cells exhibit an exaggerated inﬂammatory response.34 In either case,
the abnormal inﬂammatory response will make the host less
likely to survive to a severe infection.
It is increasingly recognized that commensal ﬂora plays a
critical role in host metabolic and immune homeostasis. The
intestinal microbiota participates in nutrient harvesting and interacts with the host epithelial and immune cells to maintain the
equilibrium between tolerance toward exogenous molecules
and preparedness against pathogen invasion. This symbiosis is
particularly fascinating in the early stages of life, as the predictable, ordered assembly of the gut microbiome and its
functional capacity appear to be essential for the healthy development of the child.35–37 Many factors, including genetics,
mode of delivery, age, diet, use of antibiotics, and the mother’s
microbiome, can affect the infant gut microbiota composition.
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However, the interindividual diversities (β-diversity) decrease with age, and after the ﬁrst 3 years of life, there is a
remarkable consistency among healthy individuals.35,37
Aberrant microbiota composition has been associated with
numerous diseases in childhood and later in life.38,39
The analysis of the fecal microbiota evolution of these
children over the 6-month follow-up showed some expected
changes in both cases and controls. First, the within-sample
diversity of the samples increased with age, reﬂecting the
acquisition of new bacterial strains from the environment.
Second, some of the changes in the bacterial communities
followed the predictable age-dependent pattern: Enterobacteriaceae and Biﬁdobacteriaceae, typically predominant
in the intestine of very young infants, decreased over time,
whereas members of the Lachnospiraceae expanded.35,36,39
Bacteria belonging to this family often produce short-chain
fatty acids that regulate host immunity through the induction
of regulatory T cells and help maintain enterocyte health and
have been considered markers of a healthy microbiota.40,41
Interestingly, despite the limited sample size, we were also
able to appreciate differences between the gut microbiota of
stunted and non-stunted children. First, differences in fecal
microbiota composition between cases and controls were
already present at baseline, before any child had developed
signs of clinical stunting, and persisted throughout the study
(Figure 5), possibly signifying that the intestinal microbiome is
a driver, or shares an upstream mediator, with stunting. If
changes in the gut microbiota result in decreased energy
harvesting from food, interventions aimed at restoring a
healthy commensal ﬂora may be just as important as providing
an age-appropriate diet to cure stunting. An arrest of the
maturation of intestinal microbiome has indeed already been
described in children with severe acute malnutrition.42,43
Previous studies comparing the gut microbiota of healthy
versus malnourished children have often found dissimilarities
between the groups but the bacteria identiﬁed as discriminant are not consistent, probably due to differences in age,
geography, type of malnutrition, and sample-processing
techniques.42–45 Inferring the potential signiﬁcance of such
differences is arduous: the human microbiome possesses an
extraordinary functional redundancy, and the true signiﬁcance
of changes in the relative abundance of some species needs
to be investigated with sophisticated metagenomic analyses
that were beyond the scope of this pilot study.
Our study has other limitations1: The sample size is small
and probably explains some of the nonstatistically signiﬁcant
ﬁndings.2 Our children were of slightly different ages; although
the differences were in terms of months, the tremendous pace
of changes in the physiology and microbiota characteristics of
this period of life makes them remarkable and potentially
confounds some of the results.3 The microbiome analysis was
performed on fecal samples which are not necessarily representative of the bacterial communities populating different
segments of the intestine.
In summary, we found that the clinical onset of stunting is
preceded by the appearance of markers of accelerated mucosal turnover, systemic inﬂammation, and changes in the gut
microbiota. Future studies aimed at characterizing the progressive functional maturation of the intestinal mucosa and
microbiome and their cross-talk with the developing immune
system in the early stages of life may offer new approaches for
the prevention and cure of the stunting syndrome.
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